Currently, the only rational molecular-targeted therapy for LSCC is cetuximab (C225/Eribitux), a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), which is expressed on tumor cells3. Here, EGFR is linked to neoplasm.